Browsing Tag
Roivant Sciences
6 posts
Pfizer-backed Priovant wins FDA priority review for brepocitinib in dermatomyositis
FDA grants priority review to Priovant's brepocitinib NDA for dermatomyositis with a Q3 2026 PDUFA date. Read what this means for Roivant, Pfizer, and the autoimmune market.
Organon to acquire Dermavant for $1.2bn, expanding its presence in immuno-dermatology
Organon, a global healthcare company focused on women’s health, has announced a definitive agreement to acquire Dermavant Sciences…
Roivant Sciences, Pfizer create new business for inflammatory disease drug
Roivant Sciences, a US healthcare company, and Pfizer have established a new Vant to develop and commercialize PF-06480605…
Roivant Sciences enters into $7.3bn merger with Montes Archimedes Acquisition
Roivant Sciences has agreed to merge with Montes Archimedes Acquisition (MAAC), a Nasdaq-listed special purpose acquisition company, in…
Roivant Sciences to acquire Silicon Therapeutics to boost drug discovery capabilities
Roivant Sciences has agreed to acquire Silicon Therapeutics, a Boston-based drug design, research, and development company, for $450…
Roivant Sciences launches Respivant Sciences to advance treatments for respiratory diseases
Roivant Sciences has launched a new biopharma company, Respivant Sciences, to focus on cutting-edge treatments for severe respiratory…